Illimis Therapeutics: Valuation, Funding & Investors
Illimis Therapeutics is a biotechnology company focused on developing innovative treatments for challenging cancers, Alzheimer's, and immune diseases. Leveraging its proprietary GAIA platform, the company aims to advance its drug development pipeline through strategic global partnerships, including collaborations with industry leaders like Lilly Catalyze360-ExploR&D.
Leadership & Board
- Current Number of Employees
- 29
- Current LinkedIn Followers
- 643
Latest Estimated Valuation
- Total Amount Raised
- $42M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $42M
- Latest Funding Round
- Series B
Employee Trend
Illimis Therapeutics had 29 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
29Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Illimis Therapeutics had 643 followers as of October 26, 2026. The number of followers increased by 2 (0.31%) week-over-week.
643Latest Followers Count
2(0.31%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jul 14, 2025 | Series B | $42.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Woori Venture Partners | Series B |
| DSC Investment | Series B |
| Korea Development Bank | Series B |
| Aju IB Investment | Series B |
| Quad Asset Management | Series B |
| Company K Partners | Series B |
| GS Ventures | Series B |
| Dayli Partners | Series B |
Similar Companies
A snapshot of private companies similar to Illimis Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
